CN112562810A - Plasma cell tumor disease management recording system and recording method - Google Patents
Plasma cell tumor disease management recording system and recording method Download PDFInfo
- Publication number
- CN112562810A CN112562810A CN202011479396.4A CN202011479396A CN112562810A CN 112562810 A CN112562810 A CN 112562810A CN 202011479396 A CN202011479396 A CN 202011479396A CN 112562810 A CN112562810 A CN 112562810A
- Authority
- CN
- China
- Prior art keywords
- information
- treatment
- patient
- evaluation
- module
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Abstract
The invention relates to a plasma cell tumor disease management input system and an input method, comprising an information acquisition module, an information input module, a diagnosis layering system, a treatment evaluation system, a survival system evaluation system and a data export system; the treatment information and the curative effect information of the patient are managed respectively, so that the treatment information and the curative effect information of the patient can be managed or corrected conveniently, the information of the patient can be input conveniently, all information of the patient in the treatment process can be acquired according to the basic information of the patient when the information is called, a form can be generated, great convenience is provided for the information acquisition of the patient, and great reference value is provided for later-stage treatment schemes or similar cases.
Description
Technical Field
The invention relates to a plasma cell tumor disease management entry system and an entry method, which are applied to multiple myeloma diseases, in particular to the plasma cell tumor disease management entry system and the entry method.
Background
Multiple Myeloma (MM) is a malignant disease in which seed plasma cells abnormally proliferate, is a common malignancy at 2 nd in the blood system in many countries, is frequently found in old people, and is not cured at present. With the continuous emergence of new drugs and the improvement of detection means, the diagnosis and treatment of multiple myeloma are continuously improved and perfected. Chimeric antigen receptor T cell (CAR-T) immunotherapy has been partially augmented in refractory relapsed multiple myeloma, emphasizing that autologous hematopoietic stem cell transplantation (ASCT) is still irreplaceable for suitable transplant patients. The updating of Chinese multiple myeloma diagnosis and treatment guidelines for 1 time every 2-3 years has important significance for improving the diagnosis and treatment level of Chinese multiple myeloma.
The standard IAWG potency of the traditional IMWC therapeutic criteria is as follows:
1. complete remission in the strict sense (sCR): on the basis of satisfying the CR criteria, the ratio of serum Free Light Chain (FLC) is normal and the absence of clonal plasma cells in the bone marrow is confirmed by immunohistochemistry. The definition of marrow clonal plasma cells is that the immunohistochemical method is used for detection, and k/lambda is continuously measured for 2 times>4:1 or<1:2 (for K-type and lambda-type patients, respectively, count > 100 plasma cells), if there is no marrow pathology, sensitivity can be up to 10-4Multi-color flow cytometry of (a) monitoring a bone marrow specimen for clonal plasma cell replacement.
CR, negative in serum and urine immune fixed electrophoresis, disappearance of soft tissue plasmacytoma, and less than 5% of plasmacytoma in bone marrow; patients who rely solely on serum FLC levels as a measurable lesion are required to return to normal for 2 consecutive assessments of serum FLC ratios, in addition to meeting the above criteria for CR.
3. Very Good Partial Response (VGPR), the M protein can not be detected by serum protein electrophoresis, but the serum and urine immune fixed electrophoresis is still positive; or a > 90% reduction in M protein and <100mg/24h in urine M protein, in patients relying only on serum FLC as a measurable lesion, in addition to meeting the criteria for VGPR above, requires a > 90% reduction in the difference between 2 consecutive affected and unaffected serum FLC.
4. Partial response.pr:
(1) the serum M protein is reduced by more than or equal to 50 percent, and the urine M protein is reduced by more than or equal to 90 percent or reduced to less than 200mg/24h after 24 h;
(2) if M protein in serum and urine can not be detected, the difference between affected and unaffected serum FLC is required to be reduced by more than or equal to 50 percent;
(3) if the M protein and the serum FLC in the serum and the urine can not be measured and the baseline bone marrow plasma cell proportion is more than or equal to 30 percent, the number of the plasma cells in the bone marrow is required to be reduced by more than or equal to 50 percent;
(4) in addition to the above criteria, if soft tissue plasmacytoma is present at baseline, it is desirable that the sum of the products of the largest vertical diameters of the measurable lesions (SPD) be reduced by > 50%. The serological and urinary M protein indexes need to be evaluated for 2 times continuously, and meanwhile, evidence of new bone lesion occurrence or original bone lesion progression does not exist.
MR (evaluation for refractory/relapsed multiple myeloma only): serum M protein decreased by 25% -49% and 24h urinary light chain decreased by 50% -89%, requiring measurable lesion SPD shrinkage by 25% -49% if soft tissue plasmacytoma is present at baseline. The number and size of osteolytic lesions did not increase (allowing compression fractures to occur).
At present, although the treatment condition and the curative effect of a patient can be evaluated, each piece of treatment information or curative effect evaluation information of the patient needs to be output separately when the treatment condition and the curative effect evaluation information are output, which brings great inconvenience to the output of patient information.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention aims to provide a plasma cell tumor disease management entry system and an entry method which are convenient for patient data input by establishing a database and respectively inputting the treatment information and the treatment effect information of a patient into different systems, can acquire a treatment effect judgment evaluation form of the patient according to the basic information of the patient during output, and provide great convenience for patient information management.
In order to achieve the above object, the present invention adopts the following technical solution, a plasma cell tumor disease management entry system, comprising:
the information acquisition module is used for inputting or importing the demographic information of all patients to form a patient information database;
the information input module is used for inputting basic information of a patient, wherein the basic information of the patient comprises sub-project related information required by a researcher, and the sub-project related information comprises diagnosis method content, research targets, treatment technology content and changes of the diagnosis method content, the research targets, the treatment technology content and the treatment technology content in the disease management process; matching all diagnosis information, treatment information and follow-up information of the patient in the disease management process according to the input basic information of the patient;
the diagnosis layering system matches the patient suffering period information of the patient during treatment according to the patient basic information input by the information input module; the diagnosis layering system comprises a DS staging system, an ISS staging system and an R-ISS staging system;
the treatment evaluation system acquires the patient treatment process information determined by the information input module and the patient suffering period information determined by the diagnosis layering system; evaluating the curative effect of the patient according to the acquired information to obtain curative effect evaluation information;
the survival system evaluation system is used for acquiring the patient treatment process information determined by the information input module and the patient suffering period information determined by the diagnosis layering system and evaluating the current survival index of the patient according to the acquired information; obtaining survival index evaluation information;
and the data export system is used for acquiring the treatment evaluation information obtained by the treatment evaluation system and the survival index evaluation information obtained by the survival system evaluation system and generating a patient curative effect judgment evaluation data table by combining the basic information of the patient.
The treatment process information comprises an MM treatment process information module and an NDMM treatment process information module.
The MM treatment process information module comprises a first treatment progress information input module for inputting treatment scheme information adopted in the MM treatment process carried out by a patient and a first curative effect evaluation module for inputting information for evaluating the treatment process in the MM treatment process;
the first treatment progress information entry module comprises a first treatment change scheme information entry module for entering the treatment change scheme information after the treatment change scheme is carried out when the MM treatment process is implemented;
the first curative effect evaluation module comprises a first original scheme evaluation module for inputting information evaluated by the treatment process in the first treatment progress information input module and a first replacement scheme evaluation module for inputting information evaluated by the replacement treatment process after the treatment scheme is replaced.
The NDMM treatment flow information module comprises a second treatment progress information input module for inputting treatment scheme information adopted in the NDMM treatment flow implemented by the patient and a second curative effect evaluation module for inputting information for evaluating the treatment flow in the NDMM treatment flow;
the second treatment progress information input module comprises a second replacement treatment scheme information input module for inputting the replacement treatment scheme information after the treatment scheme is replaced when the NDMM treatment process is implemented;
the second curative effect evaluation module comprises a second original scheme evaluation module which is used for inputting information evaluated by the treatment process in the second treatment progress information input module.
The treatment evaluation information acquired by the treatment evaluation system includes:
SCR: strictly complete mitigation information
CR: completely mitigating evaluation information;
VGPR: very good partial assessment of remission;
PR: partial mitigation evaluation information;
MR: assessment information for refractory/relapsed MM;
SD: disease stability information evaluation information;
PD: clinical relapse assessment information;
or:
persistent MRD negative evaluation information; second generation streaming MRD negative evaluation information; second generation sequencing MRD negative evaluation information; MRD negative evaluation information of original positive imaging; relapse after MRD negative.
A plasma cell tumor disease management and recording method,
s1, establishing a database, and recording the basic information and the treatment information of all patients through an information acquisition module to form a patient treatment information database;
s2, information entry, wherein entry personnel enter basic information of the patient in the information entry module;
s3, acquiring the treatment process information of the patient, and matching the specific treatment process information of the patient in the treatment process in the established database according to the basic information of the patient input in the information input module;
s4, acquiring the patient suffering period information, and matching the patient suffering period information in the diagnosis layering system;
s5, acquiring curative effect evaluation information of the patient, and matching the curative effect evaluation information of the patient in a curative effect evaluation system;
s6, matching survival system evaluation information of the patient in a survival system evaluation system according to the acquired treatment flow information, the acquired suffering period information and the acquired curative effect evaluation information of the patient;
and S7, outputting information, and generating a patient curative effect judgment evaluation form according to the obtained treatment process information, the patient stage information, the curative effect evaluation information and the survival system evaluation information of the patient.
The invention has the beneficial effects that: the treatment information and the curative effect information of the patient are managed respectively, so that the treatment information and the curative effect information of the patient can be managed or corrected conveniently, the information of the patient can be input conveniently, all information of the patient in the treatment process can be acquired according to the basic information of the patient when the information is called, a form can be generated, great convenience is provided for the information acquisition of the patient, and great reference value is provided for later-stage treatment schemes or similar cases.
Drawings
FIG. 1 is a block diagram of a curative effect judgment evaluation entry system in an embodiment of the present invention;
FIG. 2 is a block diagram of the MM treatment flow information module in an embodiment of the invention;
FIG. 3 is a block diagram of the NDMM treatment flow information module according to an embodiment of the invention.
Detailed Description
The invention is described in detail below with reference to the figures and examples.
In the description of the present invention, it is to be understood that the terms "center", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", and the like indicate orientations or positional relationships based on those shown in the drawings, and are only for convenience of description and simplicity of description, and do not indicate or imply that the referenced devices or elements must have a particular orientation, be constructed and operated in a particular orientation, and thus, are not to be construed as limiting the present invention.
The terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature; in the description of the present invention, "a plurality" means two or more unless otherwise specified.
Examples
Fig. 1 is a plasma cell tumor disease management entry system, including:
the information acquisition module 1 is used for inputting or importing the demographic information of all patients to form a patient information database;
the information acquired by the information acquisition module comprises all treatment information received by the patient during treatment, and the acquired information is classified and stored, for example, the treatment process information of the patient is stored in the information input module 2, and the affected period of the patient is stored in the corresponding diagnosis layering system 21 according to the classification and the affected period; the curative effect evaluation information of the patient in the treatment process is stored in a treatment evaluation system 3;
the information input module 2 is used for inputting basic information of a patient, wherein the basic information of the patient comprises sub-project related information required by a researcher, and the sub-project related information comprises diagnosis method content, research targets, treatment technology content and changes of the diagnosis method content, the research targets, the treatment technology content and the treatment technology content in a disease management process; matching all diagnosis information, treatment information and follow-up information of the patient in the disease management process according to the input basic information of the patient, and avoiding the data loss;
the treatment procedure information includes an MM treatment procedure information module 4 and an NDMM treatment procedure information module 5.
The MM treatment process information module 4 shown in fig. 2 includes a first treatment progress information entry module 41 for entering information on treatment protocols used in the MM treatment process performed by the patient, and a first efficacy evaluation module 42 for entering information on evaluation of the treatment process in the MM treatment process;
the first treatment progress information entry module 41 comprises a first replacement treatment scheme information entry module 43 for entering replacement treatment scheme information after a treatment scheme is replaced when an MM treatment process is implemented;
the first therapeutic effect evaluation module 42 includes a first original scheme evaluation module 44 for entering information to be evaluated by the treatment procedure in the first treatment progress information entry module 41, and a first replacement scheme evaluation module 45 for entering information to be evaluated by the replacement treatment procedure after the treatment scheme is replaced.
The NDMM treatment process information module 5 comprises a second treatment progress information input module 51 for inputting treatment scheme information adopted in the NDMM treatment process carried out by the patient, and a second curative effect evaluation module 42 for inputting information for evaluating the treatment process in the NDMM treatment process;
the second treatment progress information entry module 51 comprises a second replacement treatment scheme information entry module 53 for entering the replacement treatment scheme information after the treatment scheme is replaced when the NDMM treatment process is implemented;
the second efficacy evaluation module 52 includes a second original prescription evaluation module 54 for entering information to be evaluated by the treatment procedure in the second treatment progress information entry module 51.
The diagnosis layering system 21 matches the patient suffering period information of the patient during treatment according to the patient basic information input by the information input module 2; the diagnostic layering system 21 comprises a DS staging system 22, an ISS staging system 23 and an R-ISS staging system; the DS staging system 22, the ISS staging system 23 and the R-ISS staging classify patients according to different affected periods under different conditions, so that the classified affected periods are ensured to be closest to the patients, and data guarantee is provided for later treatment;
the treatment evaluation system 3 acquires the patient treatment process information determined by the information input module 2 and the patient suffering period information determined by the diagnosis layering system 21; evaluating the curative effect of the patient according to the acquired information to obtain curative effect evaluation information;
the treatment evaluation information acquired by the treatment evaluation system 3 includes: evaluation information evaluated by the conventional IMWG efficacy criteria:
SCR: strictly complete mitigation information
CR: completely mitigating evaluation information;
VGPR: very good partial assessment of remission;
PR: partial mitigation evaluation information;
MR: assessment information for refractory/relapsed MM;
SD: disease stability information evaluation information;
PD: clinical relapse assessment information;
or assessment information assessed by IMWG MRD efficacy criteria:
persistent MRD negative evaluation information; second generation streaming MRD negative evaluation information; second generation sequencing MRD negative evaluation information; MRD negative evaluation information of original positive imaging; relapse after MRD negative.
When the treatment of the patient is evaluated, the patient is evaluated according to the two labels, the information of the corresponding rating is stored, and the information of which evaluation system is adopted for evaluation in the treatment process can be extracted only by inputting the name of the patient;
the survival system evaluation system 6 is used for acquiring the patient treatment process information determined by the information input module 2 and the patient suffering period information determined by the diagnosis layering system 21, and evaluating the current survival index of the patient according to the acquired information; outputting the obtained survival index information;
and a data export system 7 for acquiring the treatment evaluation information obtained by the treatment evaluation system 3 and the survival index evaluation information obtained by the survival system evaluation system 6 and generating a patient curative effect judgment evaluation data table by combining the basic information of the patient. The form includes basic information of the patient, such as name, sex, age (NDMM treatment and MM treatment are performed according to age, so that further search for treatment process information can be judged according to age), disease date, treatment process information, treatment data information of each disease period of the patient in the treatment process, treatment evaluation information and survival evaluation information of the patient in the treatment process, and the treatment scheme and treatment effect adopted by the patient in the treatment process can be intuitively obtained through the generated form, so that data reference is provided for the later treatment scheme.
A plasma cell tumor disease management entry method is characterized in that:
s1, establishing a database, and recording the basic information and the treatment information of all patients through the information acquisition module 1 to form a patient treatment information database;
s2, information entry, wherein entry personnel enter basic information of the patient in the information entry module 2;
s3, acquiring the treatment process information of the patient, and matching the specific treatment process information of the patient in the treatment process in the established database according to the basic information of the patient input in the information input module 2;
s4, acquiring the patient suffering period information, and matching the patient suffering period information in the diagnosis layering system 21;
s5, acquiring curative effect evaluation information of the patient, and matching the curative effect evaluation information of the patient in a curative effect evaluation system 3;
s6, matching survival system evaluation information of the patient in the survival system evaluation system 6 according to the acquired treatment flow information, the illness state information and the curative effect evaluation information of the patient;
and S7, outputting information, and generating a patient curative effect judgment evaluation form according to the obtained treatment process information, the patient stage information, the curative effect evaluation information and the survival system evaluation information of the patient.
The above embodiments are merely illustrative of the present invention, and should not be construed as limiting the scope of the present invention, and all designs identical or similar to the present invention are within the scope of the present invention.
Claims (6)
1. A plasma cell tumor disease management entry system, comprising:
the information acquisition module (1) is used for inputting or importing the demographic information of all patients to form a patient information database;
the information input module (2) is used for inputting basic information of a patient, the basic information of the patient comprises sub-project related information required by a researcher, and the sub-project related information comprises diagnosis method content, research targets, treatment technology content and changes of the diagnosis method content, the research targets, the treatment technology content in the disease management process; matching all diagnosis information, treatment information and follow-up information of the patient in the disease management process according to the input basic information of the patient;
the diagnosis layering system (21) matches the patient suffering period information of the patient during treatment according to the patient basic information input by the information input module (2); the diagnostic layering system (21) comprises a DS staging system (22), an ISS staging system (23), and an R-ISS staging system;
the treatment evaluation system (3) is used for acquiring the patient treatment process information determined by the information input module (2) and the patient suffering period information determined by the diagnosis layering system (21); evaluating the curative effect of the patient according to the acquired information to obtain curative effect evaluation information;
the survival system evaluation system (6) is used for acquiring the patient treatment process information determined by the information input module (2) and the patient suffering period information determined by the diagnosis layering system (21), and evaluating the current survival index of the patient according to the acquired information; obtaining survival index evaluation information;
and a data export system (7) for acquiring the treatment evaluation information obtained by the treatment evaluation system (3) and the survival index evaluation information obtained by the survival system evaluation system (6) and generating a patient curative effect judgment evaluation data table by combining the basic information of the patient.
2. The plasma cell tumor disease management entry system of claim 1, wherein the therapy procedure information comprises a MM therapy procedure information module (4) and an NDMM therapy procedure information module (5).
3. A plasma cell tumor disease management entry system according to claim 2,
the MM treatment process information module (4) comprises a first treatment progress information entry module (41) for entering treatment scheme information adopted in the MM treatment process of a patient, and a first curative effect evaluation module (42) for entering information for evaluating the treatment process in the MM treatment process;
the first treatment progress information entry module (41) comprises a first replacement treatment scheme information entry module (43) for entering replacement treatment scheme information after a treatment scheme is replaced when the MM treatment process is implemented;
the first curative effect evaluation module (42) comprises a first original scheme evaluation module (44) for inputting information evaluated by adopting the treatment flow in the first treatment progress information input module (41) and a first replacement scheme evaluation module (45) for inputting information evaluated by replacing the treatment flow after replacing the treatment scheme.
4. A plasma cell tumor disease management entry system according to claim 2,
the NDMM treatment process information module (5) comprises a second treatment progress information input module (51) for inputting treatment scheme information adopted in the NDMM treatment process carried out by the patient, and a second curative effect evaluation module (42) for inputting information for evaluating the treatment process in the NDMM treatment process;
the second treatment progress information input module (51) comprises a second replacement treatment scheme information input module (53) for inputting the replacement treatment scheme information after the treatment scheme is replaced when the NDMM treatment process is implemented;
the second curative effect evaluation module (52) comprises a second original scheme evaluation module (54) which is used for recording information evaluated by adopting the treatment flow in the second treatment progress information recording module (51).
5. A plasma cell tumour disease management entry system according to claim 1, characterised in that the treatment evaluation information acquired by the treatment evaluation system (3) comprises:
SCR: strictly complete mitigation information
CR: completely mitigating evaluation information;
VGPR: very good partial assessment of remission;
PR: partial mitigation evaluation information;
MR: assessment information for refractory/relapsed MM;
SD: disease stability information evaluation information;
PD: clinical relapse assessment information;
or:
persistent MRD negative evaluation information; second generation streaming MRD negative evaluation information; second generation sequencing MRD negative evaluation information; MRD negative evaluation information of original positive imaging; relapse after MRD negative.
6. A plasma cell tumor disease management entry method is characterized in that:
s1, establishing a database, and recording the basic information and the treatment information of all patients through the information acquisition module (1) to form a patient treatment information database;
s2, information entry, wherein entry personnel enter basic information of the patient in the information entry module (2);
s3, acquiring the treatment process information of the patient, and matching the specific treatment process information of the patient in the treatment process in the established database according to the basic information of the patient recorded in the information recording module (2);
s4, acquiring the patient suffering period information, and matching the patient suffering period information in the diagnosis layering system (21);
s5, acquiring curative effect evaluation information of the patient, and matching the curative effect evaluation information of the patient in a curative effect evaluation system (3);
s6, matching survival system evaluation information of the patient in a survival system evaluation system (6) according to the acquired treatment flow information, the illness state information and the curative effect evaluation information of the patient;
and S7, outputting information, and generating a patient curative effect judgment evaluation form according to the obtained treatment process information, the patient stage information, the curative effect evaluation information and the survival system evaluation information of the patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011479396.4A CN112562810A (en) | 2020-12-15 | 2020-12-15 | Plasma cell tumor disease management recording system and recording method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011479396.4A CN112562810A (en) | 2020-12-15 | 2020-12-15 | Plasma cell tumor disease management recording system and recording method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112562810A true CN112562810A (en) | 2021-03-26 |
Family
ID=75063905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011479396.4A Pending CN112562810A (en) | 2020-12-15 | 2020-12-15 | Plasma cell tumor disease management recording system and recording method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112562810A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103020778A (en) * | 2012-12-21 | 2013-04-03 | 中国人民解放军第三军医大学第二附属医院 | Standardized therapy management system used for hematological malignancy patients |
| CN103544148A (en) * | 2012-07-09 | 2014-01-29 | 首都医科大学宣武医院 | Patient index method and system |
| WO2015118529A1 (en) * | 2014-02-04 | 2015-08-13 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
| CN105956378A (en) * | 2016-04-26 | 2016-09-21 | 成都聚恒康科技有限公司 | Clinical decision supporting system of tumor diagnosis and treatment |
| CN106650229A (en) * | 2016-11-09 | 2017-05-10 | 中国人民解放军第二军医大学第二附属医院 | Kidney cancer case digitized information management system |
| CN107169259A (en) * | 2016-12-12 | 2017-09-15 | 为朔生物医学有限公司 | Personalized medicine based on collaborative filtering and suggestion determines support system |
| CN107330260A (en) * | 2017-06-23 | 2017-11-07 | 中国人民解放军第306医院 | A kind of patients with diabetic retinopathy clinical scale diagnosis and treatment data management system |
| CN108154907A (en) * | 2018-02-08 | 2018-06-12 | 天津优视医疗器械有限公司 | A kind of medical information input system and its method of work |
| CN108877878A (en) * | 2018-06-25 | 2018-11-23 | 荆门市第二人民医院 | A kind of information acquisition management system in oncology chemotherapy |
| CN110148471A (en) * | 2019-03-21 | 2019-08-20 | 中国人民解放军总医院第五医学中心 | Liver and gallbladder tumor patient survival rate prediction data collection system and model building method |
-
2020
- 2020-12-15 CN CN202011479396.4A patent/CN112562810A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103544148A (en) * | 2012-07-09 | 2014-01-29 | 首都医科大学宣武医院 | Patient index method and system |
| CN103020778A (en) * | 2012-12-21 | 2013-04-03 | 中国人民解放军第三军医大学第二附属医院 | Standardized therapy management system used for hematological malignancy patients |
| WO2015118529A1 (en) * | 2014-02-04 | 2015-08-13 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
| CN105956378A (en) * | 2016-04-26 | 2016-09-21 | 成都聚恒康科技有限公司 | Clinical decision supporting system of tumor diagnosis and treatment |
| CN106650229A (en) * | 2016-11-09 | 2017-05-10 | 中国人民解放军第二军医大学第二附属医院 | Kidney cancer case digitized information management system |
| CN107169259A (en) * | 2016-12-12 | 2017-09-15 | 为朔生物医学有限公司 | Personalized medicine based on collaborative filtering and suggestion determines support system |
| CN107330260A (en) * | 2017-06-23 | 2017-11-07 | 中国人民解放军第306医院 | A kind of patients with diabetic retinopathy clinical scale diagnosis and treatment data management system |
| CN108154907A (en) * | 2018-02-08 | 2018-06-12 | 天津优视医疗器械有限公司 | A kind of medical information input system and its method of work |
| CN108877878A (en) * | 2018-06-25 | 2018-11-23 | 荆门市第二人民医院 | A kind of information acquisition management system in oncology chemotherapy |
| CN110148471A (en) * | 2019-03-21 | 2019-08-20 | 中国人民解放军总医院第五医学中心 | Liver and gallbladder tumor patient survival rate prediction data collection system and model building method |
Non-Patent Citations (1)
| Title |
|---|
| 中国医师协会血液科医师分会 等；: "《中国多发性骨髓瘤诊治指南（2020年修订）》", 中国内科杂志 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seaton et al. | Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response | |
| Mellemkjér et al. | Non‐Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus | |
| Wei et al. | Dysregulation of the immune response affects the outcome of critical COVID‐19 patients | |
| JP5990254B2 (en) | Methods for monitoring and analyzing metabolic activity profiles and their diagnostic and therapeutic uses | |
| Diets et al. | A recurrent de novo missense pathogenic variant in SMARCB1 causes severe intellectual disability and choroid plexus hyperplasia with resultant hydrocephalus | |
| Vasiliadis et al. | Gender and age group differences in suicide risk associated with co-morbid physical and psychiatric disorders in older adults | |
| Ahuero et al. | Paraneoplastic conjunctival cicatrization: two different pathogenic types | |
| Roed et al. | Long-term mortality in patients diagnosed with Listeria monocytogenes meningitis: a Danish nationwide cohort study | |
| Choi et al. | Prevalence and incidence of clinically significant patulous Eustachian tube: a population-based study using the Korean National Health Insurance Claims Database | |
| Balakrishnan et al. | Efficacy of HRCT imaging vs SPECT/CT scans in the staging of malignant external otitis | |
| Cho et al. | Rheumatoid arthritis and risk of lung cancer: a nationwide cohort study | |
| Xin et al. | Identification of novel KMT2D mutations in two Chinese children with kabuki syndrome: a case report and systematic literature review | |
| Decker et al. | Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases | |
| Unwin et al. | Complementary approaches to estimation of the global burden of diabetes | |
| CN112562810A (en) | Plasma cell tumor disease management recording system and recording method | |
| Marino et al. | Inflammatory cell predominance and patterns in chronic rhinosinusitis with and without nasal polyposis patients | |
| Li et al. | Menstrually-related migraine shapes the structural similarity network integration of brain | |
| Yang et al. | Anti-N-methyl-D-aspartate receptor encephalitis associated with clear cell renal carcinoma: a case report | |
| Messelmani et al. | Limbic encephalitis associated with leucine-rich glioma-inactivated 1 antibodies | |
| Maleki Balajoo et al. | Hippocampal metabolic subregions and networks: Behavioral, molecular, and pathological aging profiles | |
| Chen et al. | A novel presentation of the acute airway: Anti‐IgLON5 disease | |
| Nabi et al. | A rare case of Erdheim-Chester disease and Langerhans cell histiocytosis overlap syndrome | |
| Zorlu et al. | Abnormal structural network communication reflects cognitive deficits in schizophrenia | |
| Ferreira et al. | Pure red cell aplasia associated with thymolipoma: complete anaemia resolution following thymectomy | |
| Iftikhar et al. | Neuromyelitis Optica as an Initial Presentation of Systemic Lupus Erythematosus in a Young Male |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |